Apixaban-Induced Hepatotoxicity.

Apixaban is widely used to prevent and manage thromboembolic disease. Due to it being fairly new in the market, we are still understanding its complete risk profile. We present a case of a 61-year-old female with no prior history of liver disease, who developed severe transaminitis shortly after the initiation of apixaban and started trending down after its discontinuation.